{"url_path":"/sec/awhl/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/926617/0000926617-26-000045-index.html","accession_number":"0000926617-26-000045","cik":"0000926617","ticker":"AWHL","issuer_name":"Aspira Women's Health Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/926617/0000926617-26-000045-index.html","primary_entity_key":"0000926617","primary_entity_name":"Aspira Women's Health Inc."},"word_count":450,"has_tables":true,"body_markdown":"**Item 5.07 Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 17, 2026, Aspira Women’s Health Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). As of the close of business on the record date for the Annual Meeting, there were 43,500,411 shares of the Company’s common stock, par value $0.001 per share, issued and outstanding and entitled to vote. There were 27,144,522 shares present in person or by proxy at the Annual Meeting, or 62.40%, constituting a quorum. The final voting results were as follows:\n\n \n\nProposal 1: Election of Directors\n\n \n\nThe Company’s stockholders elected each of the Company’s six nominees for director for a one-year term expiring at the Company’s 2026 annual meeting of stockholders and until their successors are elected and qualified, as set forth below:\n\n \n\n**NOMINEE**\n\n** **\n\n**FOR**\n\n** **\n\n** **\n\n**AGAINST**\n\n** **\n\n** **\n\n**ABSTENTIONS**\n\n** **\n\n** **\n\n**BROKER NON-VOTES**\n\n** **\n\nEllen Beausang\n\n \n\n \n\n5,989,004\n\n \n\n \n\n \n\n327,224\n\n \n\n \n\n \n\n34,689\n\n \n\n \n\n \n\n16,569,699\n\n \n\nJeffrey Cohen, M.D.\n\n \n\n \n\n5,990,548\n\n \n\n \n\n \n\n325,667\n\n \n\n \n\n \n\n34,702\n\n \n\n \n\n \n\n16,569,699\n\n \n\nJohn Fraser\n\n \n\n \n\n6,278,119\n\n \n\n \n\n \n\n38,109\n\n \n\n \n\n \n\n34,689\n\n \n\n \n\n \n\n16,569,699\n\n \n\nCynthia Hundorfean\n\n \n\n \n\n5,991,040\n\n \n\n \n\n \n\n325,188\n\n \n\n \n\n \n\n34,689\n\n \n\n \n\n \n\n16,569,699\n\n \n\nWinfred Parnell, M.D.\n\n \n\n \n\n5,989,187\n\n \n\n \n\n \n\n327,040\n\n \n\n \n\n \n\n34,690\n\n \n\n \n\n \n\n16,569,699\n\n \n\nJane Pine Wood\n\n​\n\n​\n\n5,983,931\n\n​\n\n​\n\n​\n\n332,046\n\n​\n\n​\n\n​\n\n34,940\n\n​\n\n​\n\n​\n\n16,569,699\n\n​\n\n \n\nProposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers\n\n \n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below:\n\n \n\n**FOR**\n\n** **\n\n** **\n\n**AGAINST**\n\n** **\n\n** **\n\n**ABSTENTIONS**\n\n** **\n\n** **\n\n**BROKER NON-VOTES**\n\n** **\n\n \n\n5,568,783\n\n \n\n \n\n \n\n505,829\n\n \n\n \n\n \n\n276,305\n\n \n\n \n\n \n\n16,569,699\n\n \n\n \n\nProposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan\n\n \n\nThe Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below:\n\n \n\n**FOR**\n\n** **\n\n** **\n\n**AGAINST**\n\n** **\n\n** **\n\n**ABSTENTIONS**\n\n** **\n\n** **\n\n**BROKER NON-VOTES**\n\n** **\n\n \n\n5,654,497\n\n \n\n \n\n \n\n624,233\n\n \n\n \n\n \n\n72,187\n\n \n\n \n\n \n\n16,569,699\n\n \n\n \n\nProposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm\n\n \n\nThe Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as set forth below:\n\n \n\n**FOR**\n\n** **\n\n** **\n\n**AGAINST**\n\n** **\n\n** **\n\n**ABSTENTIONS**\n\n** **\n\n** **\n\n**BROKER NON-VOTES**\n\n** **\n\n \n\n22,810,174\n\n \n\n \n\n \n\n15,244\n\n \n\n \n\n \n\n95,198\n\n \n\n \n\n \n\n0\n\n \n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDated: June 17, 2026\n\n​\n\n \n\n**ASPIRA WOMEN’S HEALTH INC.**\n\n \n\n \n\n \n\n \n\nBy:\n\n*/s/ John Strahley*\n\n \n\nName: \n\nJohn Strahley\n\n \n\nTitle:\n\nChief Financial Officer\n\n​\n\n​\n\n​"}